Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
Annalisa Ciabattini, G Pastore, Fabio Fiorino, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 97

Showing 51-75 of 97 citing articles:

Age, Sex and BMI Relations with Anti-SARS-CoV-2-Spike IgG Antibodies after BNT162b2 COVID-19 Vaccine in Health Care Workers in Northern Greece
Paraskevi Papaioannidou, Kalypso Skoumpa, Christos Bostanitis, et al.
Microorganisms (2023) Vol. 11, Iss. 5, pp. 1279-1279
Open Access | Times Cited: 7
Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review
Kin Israel Notarte, Israel Guerrero‐Arguero, Jacqueline Veronica Velasco, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 16
Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study
Bumi Herman, Martin C. S. Wong, Pramon Viwattanakulvanid
PLoS ONE (2022) Vol. 17, Iss. 7, pp. e0271385-e0271385
Open Access | Times Cited: 11
Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2
Elena Pettini, Donata Medaglini, Annalisa Ciabattini
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of IFNγ-releasing cells: An exploratory study
Eugenio Garofalo, Flavia Biamonte, Camillo Palmieri, et al.
PLoS ONE (2023) Vol. 18, Iss. 2, pp. e0281444-e0281444
Open Access | Times Cited: 6
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
Rapisa Nantanee, Puneyavee Aikphaibul, Peera Jaru-Ampornpan, et al.
Vaccine (2022) Vol. 40, Iss. 24, pp. 3320-3329
Open Access | Times Cited: 10
Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses
Amanda Izeli Portilho, Gabrielle Gimenes Lima, Elizabeth De Gaspari
Journal of Clinical Medicine (2022) Vol. 11, Iss. 6, pp. 1503-1503
Open Access | Times Cited: 9
Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases
Keren M. Rabinowitz, Michal Navon, Hadar Edelman-Klapper, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1186-1186
Open Access | Times Cited: 9
Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
Michael Jahn, Johannes Korth, Oliver Dorsch, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 327-327
Open Access | Times Cited: 8
Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals
Zion Congrave‐Wilson, Wesley A. Cheng, Yesun Lee, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 813-813
Open Access | Times Cited: 8
Approaches to evaluate the specific immune responses to SARS-CoV-2
Ana López-Gomez, Hector F. Pelaez-Prestel, Ignacio Juárez
Vaccine (2023) Vol. 41, Iss. 43, pp. 6434-6443
Open Access | Times Cited: 4
High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium
Bas Calcoen, Nico Callewaert, Aline Vandenbulcke, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1257-1257
Open Access | Times Cited: 7
Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study
José Javier Morales‐Núñez, Mariel García‐Chagollán, José Francisco Muñoz‐Valle, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 4449-4466
Open Access | Times Cited: 7
Correlation of antigen-specific immune response with disease severity among COVID-19 patients in Bangladesh
Taufiqur Rahman Bhuiyan, Hasan Al Banna, M. Hasanul Kaisar, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
SARS-CoV-2 Spike Protein-Activated Dendritic Cell-Derived Extracellular Vesicles Induce Antiviral Immunity in Mice
Anjali Barnwal, Brohmomoy Basu, Aarti Tripathi, et al.
ACS Biomaterials Science & Engineering (2022) Vol. 8, Iss. 12, pp. 5338-5348
Closed Access | Times Cited: 7
Coronavirus Disease 2019 Messenger RNA Vaccines Associated With Delayed Onset of Breakthrough Infections and Fewer Radiographic Abnormalities
Xin Li, Jacky Man Chun Chan, Bosco Lam, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 1, pp. e905-e908
Open Access | Times Cited: 6
Review of Immunologic Manifestations of COVID-19 Infection and Vaccination
Valeriya Pozdnyakova, Brittany Weber, Susan Cheng, et al.
Cardiology Clinics (2022) Vol. 40, Iss. 3, pp. 301-308
Open Access | Times Cited: 6
Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Frontiers in Drug Discovery (2022) Vol. 2
Open Access | Times Cited: 6
Modulation of the Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination by Nonsteroidal Anti-Inflammatory Drugs
Carsten Skarke, Ronan Lordan, Kayla Barekat, et al.
Journal of Pharmacology and Experimental Therapeutics (2023) Vol. 386, Iss. 2, pp. 198-204
Open Access | Times Cited: 3
Significance of Anti-COVID-IgA antibody response in COVID-19 breakthrough infection in vaccinated patients – a single-centered study from Pakistan
Sabiha Anis, Mariam Ashfaq Khan, Areej Fatima, et al.
Immunologic Research (2023) Vol. 71, Iss. 6, pp. 941-949
Closed Access | Times Cited: 3
Recent Advancement of Nanostructured Materials for Clinical Challenges in Vaccinology
Mohammad Harun‐Ur‐Rashid, Israt Jahan, Abu Bin Imran
Springer eBooks (2023), pp. 135-160
Closed Access | Times Cited: 3
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
F Panza, Fabio Fiorino, G Pastore, et al.
Microorganisms (2023) Vol. 11, Iss. 10, pp. 2607-2607
Open Access | Times Cited: 3
The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose
Fabio Fiorino, Anna Sicuranza, Annalisa Ciabattini, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 8
SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History
Steven J. Drews, Queenie Hu, Reuben Samson, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 5
mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19
Federica Zavaglio, Irene Cassaniti, Josè Camilla Sammartino, et al.
Microorganisms (2022) Vol. 10, Iss. 6, pp. 1250-1250
Open Access | Times Cited: 5

Scroll to top